Preventing heart issues in elderly cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The CARTIER study is a randomized, multicenter clinical trial aimed at comparing two strategies for preventing cardiotoxicity in elderly cancer patients undergoing anti-tumoral treatment. It evaluates the effectiveness of intensive cardiovascular monitoring and multidisciplinary management against the current standard practice, which lacks routine monitoring. The primary goal is to determine if the proactive approach can reduce all-cause mortality compared to conventional care. Secondary objectives include assessing the impact on cardiovascular and oncological mortality rates.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \> 65 years old
* Expected survival \>1 year
* Colon cancer, breast cancer, lymphoma, chronic lymphoma leukemia, chronic myeloid leukemia, myeloma
* Signature on the informed consent

Exclusion Criteria:

* Patients included in clinical trials will be excluded if they interfere with the CARTIER follow-up protocol. If they do not interfere they can be included
* Patients who had received previous potentially cardiotoxic anticancer treatment

Where it's running

• Complejo Asistencial Universitario de Salamanca
  Salamanca, Spain Recruiting
• Hospital Clínico Universitario de Santiago de Compostela
  Santiago de Compostela, A Coruña, Spain Not yet recruiting
• Hospital de Galdakao-Usansolo
  Galdakao, Vizcaya, Spain Not yet recruiting
• Hospital Universitario Vall d´Hebron
  Barcelona, Spain Not yet recruiting
• Hospital Universitario Reina Sofía
  Córdoba, Spain Not yet recruiting
• Hospital Universitario de La Princesa
  Madrid, Spain Not yet recruiting

Study contacts

• Study coordinator: Pedro L Sánchez, Ph. D.
• Email: plsanchez@saludcastillayleon.es
• Phone: 923 291100

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

• Radiation-related heart damage in locally advanced NSCLC tested with PET-CT

  This study tests whether PET-CT imaging with 18F-Flurpiridaz can detect early radiation-related heart damage in adults with locally advanced non-small cell lung cancer receiving standard chemoradiation.

  Recruiting Phase 2 Indiana University · Indianapolis, Indiana · NCT07761910

• Pharmacogenomic panel to predict chemotherapy- and immunotherapy-induced heart damage

  A pharmacogenomic and pharmacoepigenetic panel is being tested to see if it can predict which breast cancer patients will develop heart damage from chemotherapy or immunotherapy.

  Recruiting Beneficência Portuguesa de São Paulo · Fortaleza, Ceará and 5 other locations · NCT07663357

• Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer

  This study tests whether heart changes seen on ultrasound and blood biomarkers can detect early heart problems in women receiving standard chemotherapy and anti-HER2 therapy for early breast cancer.

  Recruiting Gazi University · Ankara, Ankara · NCT07588425

• Serial contrast cardiac MRI and biomarker testing to detect anthracycline-related heart damage

  This study tries to see if repeated contrast cardiac MRI plus blood, urine, and stool biomarker checks can find early heart damage in people getting anthracycline chemotherapy.

  Recruiting Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) · Stuttgart · NCT07528586

• Early detection of heart and blood vessel damage from cancer treatments in children and young adults

  This project tests whether newer heart and vessel imaging and stiffness tests can find treatment-related damage earlier in children, adolescents, and young adult cancer patients.

  Recruiting at 5 sites IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bologna and 4 other locations · NCT07382141

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.